Figure 2.

Signal strengths of anti-PM/Scl-75 antibodies (a), but not of anti-PM/Scl-100 antibodies (b), depend on the underlying disease. Sera from patients with diffuse systemic sclerosis (dSSc), limited systemic sclerosis (lSSc), overlap syndromes, and undifferentiated systemic sclerosis patients were analyzed by line immunoblot assay. PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; U, units; UCTD, undifferentiated connective tissue disease.